Table 3.
Prevalence of M357R and E529D Polymorphisms in Viruses from Treatment-Naive (1) and Treated (2) and (3) Groups of Distinct HIV-1 Subtypes and Recombinant Forms
| M357R % (n) | E529D % (n) | |||||
|---|---|---|---|---|---|---|
| Subtype/CRF | Treatment naive (1) | Treated (2)a | Treated (3)a | Treatment naive (1) | Treated (2) | Treated (3) |
| HIV-1A | 17 (99/596) | 14 (5/35) | 19 (7/36) | 61 (82/135) | — | — |
| HIV-1B | 1.3 (36/2,763) | 0.6 (4/689) | 1.7 (59/3,378) | 1.1 (23/2,008) | 4.1 (10/241) | 3.3 (4/121) |
| HIV-1C | 24 (337/1,416) | 42 (32/76) | 29 (65/226) | 3.2 (30/951) | — | 3.8 (3/80) |
| HIV-1D | 6.6 (21/320) | 5.9 (1/17) | 0 (0/23) | 3.4 (1/29) | — | — |
| HIV-1F | 54 (32/59) | — | 14 (5/35) | 0 (0/16) | — | — |
| HIV-1G | 90 (130/145) | — | 89 (16/18) | 3.4 (1/29) | — | — |
| CRF01_AE | 2.2 (19/861) | 3.3 (2/61) | 11 (4/35) | 5.7 (39/687) | 0 (0/18) | — |
| CRF02_AG | 34 (216/638) | 34 (10/29) | 33 (49/149) | 94 (81/86) | — | 86 (6/7) |
Numbers in bold are significantly different from the Treatment-naive viruses at the p < .05 level.
a
Treated (2) and treated (3) refer to groups of NRTI-experienced and of NRTI+NNRTI-experienced patients, respectively, as described in the Methods section.
NRTI+NNRTI, nonnucleoside reverse transcriptase inhibitors.